Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib vs high-dose imatinib in CP-CML with suboptimal response to imatinib 400 mg
CTR20130907Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by Novartis. Started Nov 2015; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on CTR20130907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130907.